Stochter | Your Place for Smart Finance News, Investing Tips & Community

Latest

Agilent Expands Hematologic Cancer Profiling Portfolio with New Pan Heme NGS Solution Agilent Technologies (NYSE: A) launched SureSelect Cancer Research

Agilent Technologies (NYSE: A) launched SureSelect Cancer Research Pan Heme, a new next-generation sequencing research solution designed for comprehensive genomic profiling of hematologic malignancies....

11-10-26

Diamondback Energy and KKR to Acquire Full Ownership of Deep Blue Midland Basin Diamondback Energy (NASDAQ: FANG) and KKR agreed

Diamondback Energy (NASDAQ: FANG) and KKR agreed to jointly acquire Five Point Infrastructure’s 70% stake in Deep Blue Midland Basin, giving the two companies...

11-10-26

IHG Reaches 50 Open voco Hotels in Europe as Premium Brand Expansion Continues InterContinental Hotels Group (NYSE: IHG) said its

InterContinental Hotels Group (NYSE: IHG) said its voco brand has reached 50 open hotels across Europe, marking a major expansion milestone eight years after...

11-10-26

Lockheed Martin Reaches 100,000 GMLRS Rocket Milestone as Production Accelerates Lockheed Martin (NYSE: LMT) reached a major production milestone for

Lockheed Martin (NYSE: LMT) reached a major production milestone for its GMLRS precision-strike rocket program, delivering its 100,000th rocket while increasing annual production to...

11-10-26

Uber and McDonald’s Expand Delivery and Loyalty Partnership Across 14 Markets Uber Technologies (NYSE: UBER) and McDonald’s (NYSE: MCD) expanded

Uber Technologies (NYSE: UBER) and McDonald’s (NYSE: MCD) expanded their global partnership under a multi-year agreement covering 14 markets, adding deeper delivery integration and...

11-10-26

ServiceNow Adds Agentic AI for Continuous Enterprise Control Monitoring ServiceNow (NYSE: NOW) introduced new agentic AI capabilities for continuous control

ServiceNow (NYSE: NOW) introduced new agentic AI capabilities for continuous control monitoring within its Integrated Risk Management platform, allowing organizations to monitor, interpret and...

11-10-26

IBM and Microsoft Launch Imagine Enterprise Agentic AI Platform for Industry-Specific Workflows IBM (NYSE: IBM) and Microsoft (NASDAQ: MSFT) launched

IBM (NYSE: IBM) and Microsoft (NASDAQ: MSFT) launched Imagine Enterprise, a new agentic AI platform designed to help companies build, deploy and govern AI...

11-10-26

Abbott Wins FDA Approval and CE Mark for UltiSynq Defibrillation Lead Abbott (NYSE: ABT) received both U.S. FDA approval and

Abbott (NYSE: ABT) received both U.S. FDA approval and CE Mark for UltiSynq, a new implantable cardioverter-defibrillator lead designed to deliver conduction system pacing...

11-10-26

Microchip Launches High-Speed Tactile Sensor Chip for Robotics and Physical AI Microchip Technology (NASDAQ: MCHP) introduced the ATFCD52, a high-speed

Microchip Technology (NASDAQ: MCHP) introduced the ATFCD52, a high-speed capacitance digitizer designed to improve tactile sensing in robotic grippers, humanoid hands and other physical...

11-10-26

Carrier Launches SimplyFRESH Controlled Atmosphere System for Short-Haul Reefer Shipping Carrier Global (NYSE: CARR) introduced SimplyFRESH, a new controlled-atmosphere system

Carrier Global (NYSE: CARR) introduced SimplyFRESH, a new controlled-atmosphere system designed to help protect perishable cargo transported in refrigerated containers on voyages of fewer...

11-10-26

Johnson & Johnson Reports Second Positive Phase 3 Study for CAPLYTA in Bipolar Mania Johnson & Johnson (NYSE: JNJ) reported

Johnson & Johnson (NYSE: JNJ) reported positive results from a second pivotal Phase 3 study of CAPLYTA in adults with bipolar I disorder experiencing...

11-10-26

Rockwell Automation Launches PanelView Pro to Modernize Industrial HMI Systems Rockwell Automation (NYSE: ROK) introduced PanelView Pro, a new high-performance

Rockwell Automation (NYSE: ROK) introduced PanelView Pro, a new high-performance graphic terminal designed to help manufacturers modernize aging human-machine interface systems while reducing redevelopment...

11-10-26

S&P 500

U.S. CPI Rises More Than Expected in October as Core Inflation Holds at 0.3%

U.S. consumer prices rose 0.4% month over month in October, above the 0.3% forecast but slowing from September’s 0.6% increase.

Core CPI, which excludes food and energy, increased 0.3%, also exceeding the 0.2% forecast and matching the previous month’s pace.

Separately, ADP’s weekly employment measure showed private payrolls increasing by 19,800, slightly above the previous reading of 19,500.

U.S. equities traded modestly lower following the data. The S&P 500 was down 0.19%, the Dow Jones Industrial Average fell 0.35%, and the Nasdaq declined 0.06%.

The hotter-than-expected headline and core CPI readings suggest underlying inflation pressures remain persistent, potentially reinforcing expectations that the Federal Reserve will remain cautious about further monetary-policy easing.

💬

WS Investor 11-10-26

U.S. Jobless Claims Fall to 189,000 as Tech Stocks Slide

U.S. initial jobless claims fell to 189,000, below the 197,000 forecast and down from 195,000 previously, pointing to continued resilience in the labor market.

Continuing jobless claims, however, increased to 1.718 million from 1.695 million, slightly above the 1.710 million forecast. The combination suggests layoffs remain low, while workers already unemployed may be taking somewhat longer to find new jobs.

U.S. equities traded mixed following the data. The Dow Jones Industrial Average rose about 0.54%, while the S&P 500 fell 0.32% and the Nasdaq declined 1.12%.

The stronger initial claims reading may reinforce expectations that the labor market remains relatively firm, potentially limiting the case for faster monetary easing. The heavier decline in the Nasdaq suggests rate-sensitive technology stocks were under greater pressure, while the Dow showed relative strength.

💬

The Investor 11-05-26

U.S. Stock Futures Rally After Democratic Midterm Sweep as ADP Employment Matches Prior Month

U.S. stock futures moved sharply higher on Wednesday as investors digested the Democratic sweep of both chambers of Congress and a stronger-than-expected private-sector employment report.

Dow futures climbed about 2.1%, S&P 500 futures rose 1.1%, while Nasdaq futures gained 0.4%. The broader move followed confirmation that Democrats won control of both the House and Senate in the November 3 midterm elections, creating a divided government with Republican President Donald Trump.

Labor-market data also provided support. ADP reported that U.S. private payrolls increased by 86,000 in October, matching the previous month’s reading and exceeding the 67,000 forecast. The result points to continued hiring momentum, although employment growth remains relatively moderate.

The market reaction suggests investors are balancing two themes. The election outcome has increased expectations that large legislative changes may become more difficult, while the ADP report indicates the labor market has not weakened sharply. Together, those factors supported cyclical shares and helped push Dow futures substantially higher.

The Nasdaq’s smaller gain also reflects a more complicated post-election backdrop for technology stocks. Democratic victories have increased investor focus on possible tighter oversight of AI infrastructure and data-center development, particularly after election campaigns in several states highlighted concerns over energy use, utility costs and local opposition to new data centers.

Overall, the combination of greater political clarity and resilient employment data is supporting U.S. equities ahead of the opening bell. However, investors are likely to remain focused on how the new congressional balance may affect fiscal policy, AI regulation and future Federal Reserve decisions.

💬

WS Investor 11-04-26

U.S. Stocks Rise as Oil Plunges and ISM Manufacturing Beats Forecasts

U.S. stocks extended gains Monday as sharply lower oil prices eased inflation concerns and stronger-than-expected ISM manufacturing data supported confidence in the economy.

The Dow Jones rose 1.03% to 52,304.31, the Nasdaq gained 0.87% to 25,658.79, and the S&P 500 advanced 0.62% to 7,627.00.

Brent crude fell more than 6% to around $106.41 a barrel. The sharp decline in energy prices provides a favorable backdrop for equities by reducing concerns over fuel-driven inflation and potentially lowering costs for businesses and consumers.

Economic data also offered support. The ISM Manufacturing PMI increased to 55.5 in October, beating the 54.5 forecast and improving from 54.5 previously. The reading remained well above the 50 threshold, indicating continued expansion in U.S. manufacturing activity.

At the same time, the ISM Manufacturing Prices index eased to 75.2 from 77.9 and came in below the 77.2 forecast. Although input-price pressures remained elevated, the decline provided some reassurance on the inflation outlook. Manufacturing employment slipped slightly to 52.4 from 52.7 but remained in expansion territory.

Construction spending was the major weak point, falling 1.9% month over month in September compared with expectations for a 0.4% increase and a previous 2.0% gain.

Overall, the rise in U.S. indexes appears to reflect a combination of sharply lower oil prices, stronger manufacturing activity and some moderation in manufacturing price pressures. The weak construction spending figure limited the otherwise positive macro picture but was not enough to offset the broader improvement in investor sentiment.

💬

European Investor 11-02-26

U.S. Stocks Trade Mixed as Wider Trade Deficit Offsets Inventory Growth

U.S. stocks were mixed after fresh economic data showed a wider-than-expected goods trade deficit alongside stronger retail inventory growth. The S&P 500 rose 0.15% and the Dow gained 0.27%, while the Nasdaq was nearly unchanged, down 0.01%.

The U.S. goods trade deficit widened to $134.90 billion in September, larger than the $130.40 billion consensus estimate and the previous $132.07 billion deficit. The deterioration suggests imports continued to outpace exports and could weigh on the trade component of third-quarter GDP calculations.

Retail inventories excluding autos increased 0.4% in September, accelerating from 0.1% previously. Higher inventories can provide some near-term support to GDP, although persistent inventory accumulation can become a negative signal if it reflects weaker-than-expected final demand.

Overall, the releases offered a mixed economic signal: stronger inventory accumulation was offset by a larger trade deficit, helping explain the relatively subdued reaction across major U.S. equity indexes.

💬

WS Investor 10-28-26

Wall Street Rises as Strong Consumer Confidence Offsets Mixed U.S. Economic Data

U.S. stocks moved higher Tuesday, with the Nasdaq gaining 1.19%, the S&P 500 rising 0.66% and the Dow Jones adding 0.14%, as investors digested a mixed batch of economic data.

Conference Board Consumer Confidence climbed to 91.7 in October, well above the 81.2 forecast and up from 84.2 previously. The stronger-than-expected reading pointed to improved household sentiment and provided the clearest positive signal from the day’s releases.

New home sales also came in better than expected at an annualized 676,000 in September, compared with the 651,000 forecast, although sales edged down from 680,000 previously.

Other indicators were softer. Building permits slipped to 1.398 million, slightly below the 1.400 million forecast and 1.403 million prior reading. Weekly ADP employment growth slowed to 16,800 from 18,500, suggesting some moderation in private-sector hiring.

Durable goods orders rose 1.8% in September, a sharp improvement from the prior 0.1% increase but slightly below the 2.0% consensus estimate.

Overall, the data presented a mixed economic picture, with stronger consumer confidence and housing demand offsetting softer employment and building activity. The stronger move in the Nasdaq suggests risk appetite remained relatively firm despite the uneven macro signals.

💬

European Investor 10-27-26

Wall Street Falls as Mixed Jobless Claims and Surging Oil Keep Rate and Inflation Concerns in Focus

U.S. stocks traded lower after the latest labor-market data sent a mixed signal while a sharp rise in crude oil added to inflation concerns.

Initial jobless claims fell to 194,000, better than the 200,000 consensus estimate and down from 200,000 previously. The reading suggests layoffs remain relatively contained and the labor market is still holding up.

Continuing jobless claims, however, rose to 1.728 million, above the 1.720 million forecast and up from 1.703 million previously. That points to some difficulty for unemployed workers in finding new jobs even as new layoffs remain low.

Equities were under pressure, with the S&P 500 down about 0.78%, the Dow Jones Industrial Average off 0.15%, and the Nasdaq falling roughly 1.42%. The heavier Nasdaq decline suggests continued pressure on rate-sensitive growth and technology stocks.

At the same time, Brent crude climbed about 2.4% to $111.48 per barrel. Higher oil prices can complicate the inflation outlook by increasing energy and transportation costs, potentially reinforcing concerns that the Federal Reserve may need to keep monetary policy restrictive for longer.

Overall, the combination of resilient initial claims and rising oil prices appears to be weighing on risk appetite, even as the increase in continuing claims points to some underlying softening in the labor market.

💬

WS News 10-22-26

Wall Street Trades Mixed as Hotter PPI and Strong Retail Sales Reinforce Rate Concerns

U.S. stocks traded mixed after a batch of economic data showed stronger consumer spending, hotter producer inflation and continued labor-market resilience. The S&P 500 fell 0.26% to 7,698.99 and the Nasdaq dropped 0.86% to 26,463.05, while the Dow Jones Industrial Average rose 0.55% to 51,907.65.

September retail sales increased 0.8% month over month, well above the 0.3% consensus estimate, although growth slowed from 1.3% previously. Core retail sales rose 0.9%, also beating the 0.6% forecast but easing from 1.4%.

Inflation data were more concerning. Producer prices jumped 1.3% month over month, more than double the 0.6% expected and sharply above the prior 0.5% increase. Core PPI rose 0.7%, compared with a 0.3% forecast and 0.2% previously.

The labor market remained firm. Initial jobless claims were 199,000, matching expectations and little changed from 198,000, while continuing claims came in at 1.710 million, exactly in line with forecasts and slightly below 1.714 million previously.

Manufacturing data were also much stronger than expected, with the New York Empire State Manufacturing Index jumping to 25.5 in October from 7.6, far above the 12.1 consensus estimate.

The data combination points to an economy that remains resilient but is also experiencing renewed inflation pressure. That backdrop may reinforce expectations for interest rates to remain elevated for longer, which appears to be weighing particularly on the rate-sensitive Nasdaq even as the Dow moves higher.

💬

The Investor 10-15-26

Wall Street Falls as September Inflation Comes in Hotter Than Expected

U.S. stocks moved lower after September inflation data showed broader price pressures remained firmer than economists expected. The S&P 500 fell 0.76% to 7,745.85, while the Nasdaq dropped 0.99% to 26,934.31. The Dow Jones Industrial Average declined 0.14% to 51,597.18.

Headline CPI increased 0.6% month over month in September, matching expectations but accelerating from 0.4% in August. On a year-over-year basis, inflation rose to 3.7%, above the 3.6% consensus estimate and up from 3.4% previously.

More importantly for the Federal Reserve outlook, core inflation also came in hotter than expected. Core CPI rose 0.3% month over month versus the 0.2% forecast, while the annual core rate accelerated to 2.6% from 2.4%, also exceeding the 2.5% consensus estimate.

The combination of higher headline inflation and an upside surprise in core prices suggests underlying inflation pressures remain persistent. That could reduce expectations for near-term monetary easing or reinforce the case for keeping interest rates elevated for longer.

The Nasdaq’s larger decline is consistent with renewed rate concerns weighing more heavily on growth and technology stocks, while the relatively smaller move in the Dow suggests a more defensive market response.

💬

Global Finance News 10-14-26

Wall Street Trades Mixed as U.S. Housing Data Beats Expectations

U.S. stocks traded mixed Tuesday as investors digested stronger-than-expected housing data alongside another increase in weekly private-sector employment.

The S&P 500 slipped 0.07% to 7,801.82, while the Nasdaq Composite fell 0.11% to 27,217.00. The Dow Jones Industrial Average was slightly higher, gaining 0.04% to 51,868.87.

U.S. existing home sales increased to an annualized 3.99 million units in September, above expectations of 3.95 million and up from 3.93 million previously. On a monthly basis, sales rose 1.5%, significantly stronger than the expected 0.8% decline and reversing the previous month’s 3.2% drop.

Separately, ADP’s weekly employment measure showed private payrolls increasing by 24,800, up from 23,800 in the previous reading.

The data points to continued resilience in parts of the U.S. economy, particularly housing and employment. However, the relatively muted equity-market reaction suggests investors remain cautious about how stronger economic activity could influence the Federal Reserve’s interest-rate outlook.

💬

European Investor 10-13-26

11-10-26European Investor

11-09-26WS News

11-06-26WS Investor

NYSE:A

Agilent Expands Hematologic Cancer Profiling Portfolio with New Pan Heme NGS Solution

Agilent Technologies (NYSE: A) launched SureSelect Cancer Research Pan Heme, a new next-generation sequencing research solution designed for comprehensive genomic profiling of hematologic malignancies.

Developed with Roswell Park Comprehensive Cancer Center, the platform combines DNA and RNA profiling with automated sample preparation and integrated bioinformatics. It is designed to streamline molecular profiling workflows for blood cancers while reducing hands-on laboratory work.

SureSelect Cancer Research Pan Heme analyzes 359 DNA genes and 124 RNA genes and can assess several major genomic alteration classes, including single-nucleotide variants, insertions and deletions, copy-number variants, immunoglobulin translocations and gene fusions.

Agilent said Roswell Park’s current implementation of the integrated laboratory and informatics workflow can generate sample-to-report results in approximately 48 hours.

The system can also be paired with Agilent’s Magnis NGS Prep System for automated library preparation and target enrichment, while QIAGEN Clinical Insight supports variant analysis and reporting. Manual and semi-automated configurations are available for laboratories with different throughput requirements.

The launch expands Agilent’s cancer research portfolio alongside SureSelect Cancer Research CGP for solid tumors and SureSelect Human All Exon V8 for broader genomic profiling.

SureSelect Cancer Research Pan Heme is intended for research use only and is not approved for diagnostic procedures.

💬

WS Investor 11-10-26

Agilent Expands Oligonucleotide Manufacturing Capacity With New Boulder Lab

Agilent Technologies (NYSE: A) announced the opening of additional laboratory space in Boulder, Colorado, to expand its oligonucleotide manufacturing capabilities and support emerging production technologies for advanced therapeutics.

The new facility will initially focus on enzymatic ligation, a process that uses enzymes to join shorter oligonucleotide fragments into longer therapeutic molecules. Agilent said the approach could complement traditional solid-phase phosphoramidite synthesis and provide greater flexibility depending on a program’s scale and technical requirements.

Through its Advanced Therapeutics Division, Agilent provides development and cGMP manufacturing services for oligonucleotide therapies, including siRNA and antisense oligonucleotides. The Boulder expansion will complement the company’s existing operations in Colorado and broader manufacturing capabilities in Canada.

Agilent expects initial customer programs to begin at the new laboratory in November 2026, subject to operational and regulatory requirements.

The expansion strengthens Agilent’s position in the growing oligonucleotide therapeutics market as drug developers seek more scalable and flexible manufacturing methods for next-generation RNA-based treatments.

💬

The Investor 10-06-26

Agilent Launches NovoStation to Automate Flow Cytometry Sample Preparation

Agilent Technologies launched the NovoStation Sample Preparation System, a new automated platform designed to simplify and standardize flow cytometry sample preparation.

When used with Agilent’s NovoCyte flow cytometers and NovoExpress software, NovoStation creates a connected sample-to-answer workflow that automates reagent cocktailing and sample washing before moving samples directly into data acquisition.

The system is aimed at pharmaceutical, biopharmaceutical, contract research, core laboratory and academic settings where higher sample volumes and increasingly complex assays can make manual preparation time-consuming and variable.

In validation studies, NovoStation reduced hands-on preparation time by more than 90% while maintaining data quality comparable with manual processing. In a 25-color immunophenotyping workflow involving 30 samples, operator time fell to 7.9 minutes from 85.5 minutes manually. In a kappa/lambda light-chain assay, hands-on time declined to 6.8 minutes from 89.4 minutes.

Agilent said the automation can help laboratories improve reproducibility, reduce workflow bottlenecks and standardize procedures across users and sites.

The company will officially unveil NovoStation at the International Clinical Cytometry Society 2026 conference in Miami, running from October 2 through October 6.

💬

Global Finance News 10-02-26

Agilent Launches FDA-Cleared S540MD Digital Pathology Scanner in U.S.

Agilent Technologies (NYSE: A) has launched its S540MD Slide Scanner System in the United States following FDA clearance, expanding the company’s presence in the growing digital pathology market.

The S540MD is a whole-slide imaging system designed for high-volume clinical laboratories. It can hold up to 540 slides and supports continuous loading, automated scanning and advanced tissue detection, helping laboratories digitize pathology workflows at scale.

Agilent Targets AI-Enabled Pathology Growth

The launch comes as pathology laboratories increasingly adopt digital and AI-enabled diagnostic workflows to handle rising sample volumes and improve efficiency.

Agilent said the scanner is intended to integrate digital imaging with its existing pathology expertise and staining workflows. The system is an Agilent-branded version of Hamamatsu’s NanoZoomer S540MD scanner.

The U.S. rollout follows the product’s January 2026 introduction in selected European markets. For Agilent, the FDA-cleared launch expands its clinical diagnostics portfolio and positions the company to benefit from increasing adoption of digital pathology and AI-assisted laboratory workflows.

💬

The Investor 09-04-26

Agilent Launches Compact Cary 635 FTIR Spectrometer for Laboratory Analysis

Agilent Technologies (NYSE: A) announced Tuesday the launch of the Cary 635 FTIR spectrometer, a compact analytical system designed to improve laboratory efficiency while reducing space, training and maintenance requirements.

The Cary 635 uses Fourier transform infrared spectroscopy to analyze solids, liquids, powders and gases. Agilent describes the system as the smallest FTIR instrument in its class, allowing laboratories to deploy it in space-constrained environments or at different points within analytical workflows.

The system incorporates solid ZnSe optical components for improved moisture resistance and durability, while enhanced sensitivity allows lower-concentration samples to be analyzed using smaller sample volumes. A nondynamic interferometer and permanently aligned optics are designed to improve reliability and simplify maintenance.

Agilent has also emphasized ease of use. Its MicroLab software provides step-by-step, picture-guided workflows and color-coded results, allowing less-experienced laboratory personnel to operate the instrument with limited training. The optional DialPath module further simplifies liquid analysis while reducing consumables, cleaning requirements and sample volumes.

The launch expands Agilent’s spectroscopy portfolio as laboratories increasingly seek instruments that combine analytical performance with automation, smaller footprints and lower operating costs. The Cary 635 could strengthen Agilent’s position across pharmaceutical, chemical, materials and other laboratory markets where FTIR analysis is routinely used for identification and quality control.

💬

WS Investor 09-01-26

Agilent Technologies Inc. partnered with OmixAI in a three-year collaboration to advance AI-driven proteomics and precision medicine in South Korea.

The partnership will combine automation and AI to enable large-scale biological data analysis and accelerate biomarker discovery and drug development.

💬

WS Investor 04-14-26

Agilent Technologies announced the opening of a new Customer Experience Center in Mumbai, reinforcing its long-term investment and presence in India.

The facility integrates technology demonstrations, application expertise, and commercial operations, enabling customers across sectors such as pharmaceuticals, biopharma, diagnostics, and environmental testing to engage directly with Agilent’s solutions.

The center is part of Agilent’s broader strategy to expand customer-facing infrastructure globally, supporting laboratories with hands-on learning, collaboration, and advanced analytical capabilities.

Agilent said the move strengthens its role in India’s rapidly growing scientific and regulatory landscape, helping customers modernize operations and accelerate innovation.

💬

Global Finance News 04-03-26

Agilent Technologies announced it will showcase its latest advancements in precision oncology and digital pathology at the USCAP 2026 Annual Meeting in San Antonio.

The company will highlight expanded biomarker testing capabilities, including a new PD-L1 indication for ovarian-related cancers, reinforcing its focus on precision oncology. Agilent will also present end-to-end digital pathology workflows that integrate staining, imaging, and data management to improve laboratory efficiency, reproducibility, and scalability.

Additionally, Agilent emphasized collaborations with ecosystem partners such as Hamamatsu, Proscia, PathAI, and Visiopharm to support interoperable and flexible digital pathology solutions, positioning the company to advance data-driven and fully integrated pathology environments.

💬

Global Finance News 03-19-26

Agilent Technologies (A) announced the launch of Agilent Advanced Therapeutics, a unified contract development and manufacturing organization (CDMO) platform integrating its capabilities across Canada and the United States.

The new platform combines the strengths of BIOVECTRA in Canada and Agilent’s Nucleic Acid Solutions facility in Colorado to provide end-to-end development and manufacturing services for advanced therapeutics.

The offering includes manufacturing and development capabilities for oligonucleotides, microbial fermentation, synthetic chemistry, bioreagents, highly potent APIs and cell line development, enabling customers to move from early discovery through clinical and commercial production with a single partner.

💬

The Investor 03-11-26

Agilent Technologies announced it has agreed to acquire pathology solutions company Biocare Medical in an all-cash deal valued at $950 million.

Biocare specializes in clinical and research pathology tools, including immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH) solutions, and offers more than 300 specialized antibodies used in cancer diagnostics. The company generated more than $90 million in revenue in 2025 and has recorded double-digit revenue and profit growth since 2021.

Agilent said the acquisition will expand its pathology and cancer diagnostics portfolio, strengthen its antibody and reagent offerings, and enhance its ability to serve clinical and research laboratories. The transaction is expected to improve Agilent’s growth rate, margins and recurring non-instrument revenue mix, with earnings per share expected to benefit about 12 months after closing. The deal is expected to close by Agilent’s fourth fiscal quarter of 2026, subject to regulatory approvals.

💬

WS Investor 03-09-26

NYSE:MCD

Uber and McDonald’s Expand Delivery and Loyalty Partnership Across 14 Markets

Uber Technologies (NYSE: UBER) and McDonald’s (NYSE: MCD) expanded their global partnership under a multi-year agreement covering 14 markets, adding deeper delivery integration and new loyalty features.

Under the expanded relationship, Uber will become the preferred delivery fulfillment partner for orders placed directly through the McDonald’s app in participating markets including the U.S., Australia, Canada, France, Germany and the U.K. Customers will be able to place and track delivery orders without leaving the McDonald’s app.

Most McDonald’s app deliveries will be fulfilled through Uber Direct, Uber’s white-label delivery service, in partnership with Deliverect. Customers will still be able to order McDonald’s through the Uber Eats app.

The companies are also integrating their loyalty programs. Uber will serve as McDonald’s exclusive delivery and rideshare rewards partner in participating markets. MyMcDonald’s Rewards members in select markets will initially be able to redeem points for discounts on Uber rides, with broader plans to let customers earn McDonald’s points on eligible Uber Eats orders and redeem them for additional benefits.

The expanded partnership covers the U.S., Australia, Belgium, Canada, France, Germany, Ireland, the Netherlands, New Zealand, Poland, Portugal, Spain, Switzerland and the U.K.

McDonald’s said its delivery business now generates more than $20 billion annually. For Uber, the expanded agreement strengthens Uber Direct and Uber Eats by integrating them more deeply into one of the world’s largest restaurant brands and its growing digital ordering ecosystem.

💬

WS Investor 11-10-26

McDonald’s Rises 2% as Earnings Growth and International Sales Offset U.S. Weakness

McDonald’s (NYSE: MCD) shares rose about 2% after the company reported higher third-quarter earnings, solid international sales growth and a dividend increase, despite slightly negative comparable sales in the U.S.

Global comparable sales increased 1.5% in the third quarter. International Developmental Licensed Markets led growth with a 4.2% increase, while International Operated Markets rose 1.4%. U.S. comparable sales declined 0.2%, as lower guest traffic was largely offset by higher average check.

Revenue increased 1% year over year to $7.16 billion, while systemwide sales rose 4% to more than $38 billion. Operating income increased 7% to $3.60 billion, and adjusted operating income grew 8%.

Diluted EPS climbed 10% to $3.51. Excluding restructuring-related charges, adjusted EPS rose 11% to $3.57. Net income increased 9% to $2.49 billion.

McDonald’s said U.S. performance improved as the quarter progressed following renewed efforts around value offerings. International performance remained stronger, with Germany and Australia contributing to growth, while France was a partial offset. Japan led growth in developmental licensed markets, while China posted negative comparable sales.

The company also highlighted continued expansion of its loyalty ecosystem. Systemwide sales to loyalty members exceeded $11 billion during the quarter and reached $41 billion over the trailing 12 months across 70 loyalty markets.

McDonald’s raised its quarterly dividend by 4% to $1.93 per share.

The 2% share gain appears to reflect improving profitability and resilience across McDonald’s global franchise system. Stronger operating income, double-digit adjusted EPS growth and continued international momentum helped offset weak U.S. guest traffic and slower comparable-sales growth compared with the prior year.

💬

WS Investor 11-04-26

Dividend Growth Stocks: McDonald's Corporation (MCD) Dividend Stock Analysis

Your source for finding the best dividend growth stocks

(dividend-growth-stocks.com)

💬

European Investor 08-15-26

McDonald's Stock Rises 1.4% as Global Sales Growth and Loyalty Expansion Support Q2 Results

McDonald's (NYSE: MCD) shares rose 1.4% on Tuesday after the fast-food giant reported solid second-quarter results, supported by positive comparable sales across all operating segments, expanding global systemwide sales and continued momentum in its loyalty program.

Second-quarter revenue increased 4% year over year to $7.1 billion, while diluted earnings per share rose 6% to $3.32. Global systemwide sales increased 5% to $37 billion, reflecting continued consumer demand across the company's international markets.

Comparable Sales Turn Positive Across All Markets

Global comparable sales increased 1.3% during the quarter, marking positive growth across each of McDonald's major operating segments.

U.S. comparable sales rose 0.8%, driven by higher average customer spending and a favorable product mix despite lower guest traffic. International Operated Markets increased 1.5%, led by Germany, Australia and the U.K., while International Developmental Licensed Markets grew 1.9%, supported by strong performance in Japan.

The company also reported a 3% increase in operating income and a 5% increase in net income, highlighting continued operational resilience despite ongoing restructuring investments.

Loyalty Program Continues to Drive Customer Engagement

McDonald's continued expanding its digital ecosystem during the quarter.

Across 70 loyalty markets, systemwide sales generated by loyalty members over the past 12 months increased more than 20% to $40 billion. Active 90-day loyalty users also grew 13% year over year to nearly 220 million, reinforcing the company's focus on digital engagement and repeat customer activity.

Management also announced the appointment of longtime executive Skye Anderson as President of McDonald's USA, aiming to accelerate execution and improve performance in the company's largest market.

What to Watch

Investors welcomed another quarter of steady earnings growth and positive comparable sales across all segments. Going forward, markets will monitor U.S. customer traffic trends, international sales momentum, continued expansion of the loyalty platform and whether management's operational initiatives can further accelerate growth in McDonald's largest market.

💬

European Investor 08-04-26

McDonald's Edges Lower Despite Solid Q1 Beat as Investors Weigh Growth Quality

Chicago, May 7, 2026 — Shares in McDonald's Corporation dipped 0.33% on Wednesday even as the fast food giant reported a stronger-than-expected first quarter, with global comparable sales growth of 3.8% and a double-digit rise in operating income. The muted market reaction suggests investors may be scrutinizing the quality and durability of the recovery rather than simply celebrating the headline numbers.

A Broad-Based Sales Recovery

McDonald's posted consolidated revenues of $6.5 billion for the quarter ended March 31, 2026, up 9% year-over-year, or 4% in constant currencies. Systemwide sales grew 11% in reported terms, reaching 6% on a constant currency basis. Comparable sales were positive across all three of the company's reporting segments: the U.S. rose 3.9%, International Operated Markets grew 3.9%, and International Developmental Licensed Markets added 3.4%.

The U.S. rebound is particularly notable. A year ago, domestic comparable sales fell 3.6%, making this quarter's nearly 4% gain a meaningful reversal. Management attributed the improvement primarily to positive check growth, suggesting customers are spending more per visit. In the International Operated Markets, the U.K., Germany and Australia led the way, with nearly all markets reflecting positive results. Japan anchored the Developmental Licensed segment, with all geographic regions in positive territory.

CEO Chris Kempczanski pointed to the company's three-pronged approach — value leadership, marketing execution, and menu innovation — as the engine behind the results. "Our 6% global Systemwide sales growth shows how we executed with discipline, proving that we can drive results even in a challenging environment," he said.

Earnings Solid but Restructuring Costs Linger

Operating income rose 12% to $2.95 billion, or 6% in constant currencies. Net income came in at $1.98 billion, up 6%, while diluted earnings per share grew 7% to $2.78. Excluding restructuring charges tied to the company's internal modernization effort, known as Accelerating the Organization, adjusted diluted EPS was $2.83, representing 6% growth year-over-year.

Those restructuring charges — $47 million pre-tax in Q1 2026 and $66 million in the prior year period — have now appeared across multiple quarters, and while they are declining, they continue to be a line item that investors must strip out to assess underlying performance. The company's higher effective tax rate also partially offset the gains from stronger franchise margins.

Loyalty Programme Signals Long-Term Strength

One of the more compelling longer-term data points in the report was the continued momentum of McDonald's loyalty programme. Across 70 markets, systemwide sales to loyalty members exceeded $38 billion for the trailing twelve-month period, and surpassed $9 billion for the quarter alone. For a company of McDonald's scale, the ability to deepen customer relationships through digital engagement is increasingly seen as a strategic differentiator, and these figures suggest the programme is gaining meaningful traction.

Why the Stock Barely Moved

Given the breadth of the beats, the slight decline in McDonald's shares may seem counterintuitive. A few factors likely played into the muted response. First, much of the comparable sales growth, particularly in the U.S., appears to be driven by higher prices rather than increased traffic, which raises questions about volume sustainability in a cost-conscious consumer environment. Second, constant currency growth rates — the figures that strip out the benefit of a weaker dollar — tell a more modest story, with revenues up just 4% and EPS up only 1% to 2% on that basis. Third, with the stock having already appreciated in anticipation of a recovery, some degree of sell-the-news behavior is not unusual.

💬

European Investor 05-07-26

'We know that consumers' behavior changes': McDonald's prepares for wider GLP-1 adoption as weight-loss pills hit market

McDonald's CEO prepares to battle weight-loss drug pills.

(finance.yahoo.com)

💬

European Investor 02-12-26

Dividend Growth Stocks: McDonald's Corporation (MCD) Dividend Stock Analysis

Mc donalds dividend analysis ...

(dividend-growth-stocks.com)

💬

European Investor 11-08-25

McDonald’s Reports Third Quarter 2025 Results with Strong Global Sales Growth

McDonald’s Corporation reported third quarter 2025 results showing continued global momentum despite a challenging environment. Global comparable sales rose 3.6 percent, with gains across all major segments — up 2.4 percent in the U.S., 4.3 percent in International Operated Markets, and 4.7 percent in International Developmental Licensed Markets.

Global Systemwide sales reached over 36 billion dollars for the quarter, up 8 percent year over year, or 6 percent in constant currency. Loyalty program sales across 60 markets totaled approximately 9 billion dollars for the quarter and 34 billion dollars over the past twelve months. Consolidated revenues grew 3 percent, while consolidated operating income rose 5 percent, or 3 percent in constant currency.

Earnings per diluted share were 3.18 dollars, up 2 percent from the previous year. Excluding restructuring charges related to the company’s “Accelerating the Organization” initiative, adjusted earnings per share were 3.22 dollars, essentially flat compared to last year.

CEO Chris Kempczinski said McDonald’s sustained growth reflects the strength of its value-driven strategy, menu innovation, and marketing effectiveness. “We’re fueling momentum by delivering everyday value, affordability, and menu innovation that continue to bring customers through our doors,” he said.

💬

European Investor 11-05-25

How to analyse franchise stocks in 6 simple steps

Analyse franchise stocks in 6 steps ...

(fifthperson.com)

💬

Global Finance News 10-21-25

💬

WS News 06-09-25

09-06-26The Investor

05-16-26The Investor

Australia

Australia Business Confidence Slips to -15 in October

Australia’s NAB Business Confidence Index fell to -15 in October from -14 previously, signaling a further deterioration in corporate sentiment.

The negative reading indicates that businesses remain cautious about the economic outlook, with confidence still well below neutral levels.

💬

European Investor 11-10-26

Australia Building Approvals Rebound 5.1% in September, Matching Forecast

Australia’s building approvals rose 5.1% month over month in September, matching market expectations and reversing the previous 5.2% decline.

💬

WS News 11-09-26

Australia Trade Surplus Widens Sharply to A$2.83 Billion in September

Australia’s trade surplus widened sharply to A$2.826 billion in September, significantly exceeding the A$940 million forecast.

The result also marked a substantial improvement from the previous month’s A$184 million surplus.

💬

Global Finance News 11-05-26

RBA Raises Interest Rate to 4.85% in November, Matching Forecasts

The Reserve Bank of Australia raised its benchmark interest rate to 4.85% in November from 4.60%, delivering a 25-basis-point increase that matched market expectations.

💬

Global Finance News 11-03-26

Australia Building Approvals Jump 5.1% in September, Beating Forecasts

Australian building approvals rose 5.1% month over month in September, significantly exceeding the 1.8% increase expected by economists and reversing the previous month’s 5.2% decline.

💬

The Investor 11-02-26

Australia Employment Falls Sharply in September as Jobless Rate Holds at 4.7%

Australia’s labor market weakened sharply in September, with employment falling by 39,300, far below expectations for a 19,600 increase and reversing the previous month’s 29,300 gain.

The unemployment rate held at 4.7%, slightly above the 4.6% consensus estimate and unchanged from the previous month.

The composition of employment was somewhat more constructive than the headline figure suggests. Full-time employment increased by 34,400 after a 4,000 decline previously, implying that the overall employment drop was driven by a much larger fall in part-time positions.

💬

WS News 10-15-26

Australian Business Confidence Falls Further in September

Australia’s NAB Business Confidence index fell to -13 in September from -9 in the previous month, pointing to a further deterioration in business sentiment.

The deeper negative reading suggests Australian firms became more cautious about the economic outlook during the month, with confidence remaining firmly below neutral levels.

💬

The Investor 10-13-26

Australia Building Approvals Fall 6.1% in August

Australian building approvals declined 6.1% month over month in August, matching market expectations and worsening from the previous month’s 1.9% decline.

💬

WS News 10-07-26

Australia Trade Surplus Narrows Sharply in August, Missing Expectations

Australia’s trade surplus fell to A$495 million in August, well below the A$2.0 billion expected by economists and down from A$1.351 billion previously.

💬

WS News 10-01-26

Australia Building Approvals Fall 6.1% in August, Much Worse Than Expected

Australia’s building approvals fell 6.1% month over month in August, a much sharper decline than the 1.6% drop expected by economists. The previous month’s reading was revised to a 1.9% decline.

💬

WS News 09-30-26

09-02-26Global Finance News

05-19-26WS Investor

05-11-26WS Investor

05-08-26Global Finance News

04-30-26WS News

NASDAQ:AMGN

Amgen Highlights Repatha Cost-Effectiveness and Long-Term Cardiovascular Risk Reduction at AHA 2026

Amgen (NASDAQ: AMGN) presented new Repatha data at the American Heart Association Scientific Sessions 2026, strengthening the case for earlier and more intensive LDL cholesterol lowering in high-risk cardiovascular patients. :chatgpt-content-reference{index="0"}

An independent analysis of the Phase 3 VESALIUS-CV trial found Repatha to be highly cost-effective in high-risk patients without a prior heart attack or stroke, at approximately 36% below the ACC/AHA benchmark. A separate analysis also found Repatha cost-effective when added to standard therapy in patients with established atherosclerotic cardiovascular disease. :chatgpt-content-reference{index="1"}

Additional VESALIUS-CV data showed particularly strong benefits in patients with chronic kidney disease. Over a median 4.6 years, Repatha reduced the risk of three-point major adverse cardiovascular events by 39%, four-point MACE by 23% and all-cause mortality by 29% in patients with CKD and no prior heart attack or stroke. :chatgpt-content-reference{index="2"}

Amgen also presented a long-term FOURIER external-control analysis showing Repatha was associated with a 29% lower rate of major cardiovascular events and a 25% lower risk of cardiovascular death over more than eight years of follow-up. :chatgpt-content-reference{index="3"}

The new analyses reinforce Amgen’s effort to expand Repatha’s role beyond secondary prevention, supporting earlier treatment in high-risk patients and strengthening the drug’s long-term clinical and economic value proposition.

💬

European Investor 11-10-26

Amgen Slips 0.8% Premarket as Strong Q3 Growth Is Offset by Biosimilar Pressure and Lower Cash Flow

Amgen (NASDAQ: AMGN) shares fell about 0.8% in premarket trading despite reporting strong third-quarter 2026 revenue and earnings growth, as weakness in several mature products and lower free cash flow offset broad portfolio strength.

Third-quarter revenue increased 8% year over year to $10.4 billion, driven by higher product volumes. GAAP EPS rose 19% to $7.08, while non-GAAP EPS increased 14% to $6.45. GAAP operating margin expanded sharply to 37.5%, while non-GAAP operating margin improved slightly to 47.3%.

Several growth products delivered strong gains. Repatha sales increased 37% to $1.09 billion, EVENITY rose 39% to $751 million and TEZSPIRE climbed 43% to $538 million. UPLIZNA revenue surged 191% to $451 million, while IMDELLTRA increased 128% to $406 million.

However, biosimilar competition continued to weigh heavily on established products. Prolia sales fell 45% to $632 million and XGEVA declined 47% to $288 million following multiple biosimilar launches. Otezla sales also dropped 18%, while TEPEZZA declined 6%.

Free cash flow decreased to $3.7 billion from $4.2 billion a year earlier, mainly because of working-capital changes and a favorable timing benefit in the prior-year period.

The modest 0.8% premarket decline appears to reflect the mixed composition of the quarter rather than weakness in overall earnings. Amgen continues to generate strong growth across newer cardiovascular, rare disease and oncology products, but accelerating biosimilar erosion in Prolia and XGEVA, along with softer cash flow, remains an important offset to the company’s broader commercial momentum.

💬

European Investor 11-04-26

Amgen Stock Jumps 4% After Positive Phase 3 Dazodalibep Results in Sjögren’s Disease

Amgen shares rose 4% to $408.88 after the company reported positive topline results from the Phase 3 OASIZ 301 study of dazodalibep in adults with moderate-to-severe systemic Sjögren’s disease.

The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in systemic disease activity at Week 48, measured by the ESSDAI score. Amgen said improvement was visible as early as Week 4 and was sustained through Week 48.

The result is notable because there are currently no FDA-approved medicines specifically for Sjögren’s disease, creating a potentially significant commercial opportunity if dazodalibep ultimately reaches the market. The drug is designed as a CD40L antagonist fusion protein that disrupts immune-cell interactions involved in disease activity.

Safety findings were broadly manageable, with the most common adverse events including nasopharyngitis, urinary tract infection, hypertension and infusion-related reactions. Amgen said treatment discontinuations due to adverse events were low and balanced across study groups.

The company plans to present detailed OASIZ 301 data at an upcoming medical meeting, while the separate Phase 3 OASIZ 303 study is expected to complete in the fourth quarter of 2026.

💬

Global Finance News 09-22-26

FDA Approves Shorter Monitoring Period for Amgen’s IMDELLTRA Lung Cancer Treatment

Amgen said the U.S. Food and Drug Administration approved an update to the prescribing information for IMDELLTRA, significantly reducing the recommended monitoring period following the first two doses of the company’s small cell lung cancer therapy.

Under the updated label, patients should be monitored for six to eight hours from the start of their first two infusions, down from the previous recommendation of 22 to 24 hours. Patients will receive a follow-up assessment, including vital signs, the day after each of those doses.

The change could make IMDELLTRA easier to administer outside major treatment centers. Amgen noted that an estimated 80% to 85% of U.S. cancer patients receive care in community oncology settings, where lengthy monitoring requirements can complicate treatment.

IMDELLTRA is a first-in-class targeted immunotherapy designed to bind DLL3 on tumor cells and CD3 on T cells, activating the immune system against DLL3-expressing small cell lung cancer cells. It is approved for adults with extensive-stage small cell lung cancer whose disease has progressed during or after platinum-based chemotherapy.

The FDA decision follows Amgen’s recent announcement of positive overall-survival results from the Phase 3 DeLLphi-305 study evaluating IMDELLTRA with Imfinzi in first-line extensive-stage small cell lung cancer.

💬

WS Investor 09-14-26

Amgen’s IMDELLTRA Combination Delivers Overall Survival Win in Phase 3 Lung Cancer Trial

Amgen (NASDAQ: AMGN) announced positive Phase 3 results for IMDELLTRA in extensive-stage small cell lung cancer, reporting a statistically significant and clinically meaningful improvement in overall survival when the drug was combined with AstraZeneca’s Imfinzi.

The Phase 3 DeLLphi-305 trial evaluated IMDELLTRA plus Imfinzi as first-line maintenance therapy against Imfinzi alone in patients whose disease had not progressed following initial treatment with Imfinzi, platinum-based chemotherapy and etoposide.

The study met its primary overall survival endpoint at a pre-specified interim analysis. It also achieved statistically significant and clinically meaningful improvements in progression-free survival and objective response rate.

Importantly, Amgen said the combination’s safety profile was consistent with the known profiles of the individual drugs, with no new or unexpected safety signals identified.

The 563-patient trial represents the first Phase 3 study involving a Bispecific T-cell Engager therapy to demonstrate an overall survival benefit in the first-line maintenance setting for extensive-stage small cell lung cancer.

The results could significantly expand the commercial opportunity for IMDELLTRA, which is already FDA-approved for adults with extensive-stage small cell lung cancer whose disease progressed on or after platinum-based chemotherapy. Success in DeLLphi-305 potentially moves the therapy into an earlier and considerably broader treatment setting.

Amgen plans to present detailed results at an upcoming international medical congress and submit the data to regulatory authorities.

💬

The Investor 09-08-26

Amgen Stock Plunges 9.7% as BMO Capital Downgrades Shares

Amgen (NASDAQ: AMGN) shares fell 9.7% Tuesday as the biotechnology company faced a more cautious analyst outlook, including a downgrade from BMO Capital Markets.

BMO Capital downgraded Amgen from Outperform to Market Perform while setting a $450 price target. With Amgen trading around $394.79, the target still implies approximately 14% upside from the current share price.

Separately, Cantor Fitzgerald reiterated its Neutral rating on Amgen with a $400 price target. That target is only slightly above the current share price, suggesting limited upside under Cantor’s assessment.

The combination of BMO’s downgrade and Cantor’s continued Neutral stance adds to cautious sentiment surrounding Amgen following the stock’s sharp decline.

Despite BMO’s $450 target remaining above the current market price, the move from Outperform to Market Perform represents a meaningful reduction in its conviction. With shares down nearly 10% in the session, investors will be watching for developments that could explain the sharp selloff and determine whether the decline creates a more attractive valuation or signals increased risks for the biotechnology company.

💬

The Investor 09-08-26

Amgen’s Repatha Cuts Risk of Death by 20% in High-Risk Patients

Amgen (NASDAQ: AMGN) announced Monday that its cholesterol-lowering drug Repatha reduced the risk of death by 20% among high-risk adults who had not previously suffered a heart attack or stroke, according to a pre-specified analysis of the Phase 3 VESALIUS-CV trial.

The study included more than 12,000 patients and evaluated Repatha alongside statins or other LDL cholesterol-lowering treatments. Amgen said the drug produced meaningful reductions in both all-cause and cardiovascular mortality, with the mortality benefit beginning to emerge after approximately 1.5 years and continuing through a median follow-up of 4.6 years.

The findings make Repatha the first PCSK9 inhibitor to demonstrate a reduction in all-cause mortality in a Phase 3 trial involving high-risk primary-prevention patients, according to Amgen. The results were presented at the European Society of Cardiology Congress 2026 and simultaneously published in Circulation.

Additional analyses strengthened the cardiovascular case for Repatha. The treatment reduced first, subsequent and total cardiovascular events, while a reduction in heart-attack risk was observed as early as six months after treatment began. The benefit was primarily associated with fewer heart attacks caused by atherosclerotic plaque rupture and fewer larger infarctions.

The results could strengthen Repatha’s position in the cardiovascular market by supporting earlier and more aggressive LDL reduction before patients experience their first major cardiovascular event. Amgen also presented real-world studies showing that many high-risk patients remain undertreated and fail to reach recommended LDL cholesterol targets, suggesting a potentially significant population that could benefit from more intensive lipid-lowering therapy.

💬

The Investor 08-31-26

Amgen and AstraZeneca Report Positive Phase 3 TEZSPIRE Results in Eosinophilic Esophagitis

Amgen (NASDAQ: AMGN) and AstraZeneca reported positive Phase 3 results for TEZSPIRE in patients with eosinophilic esophagitis (EoE), potentially opening another major indication for the drug.

In the CROSSING trial, TEZSPIRE achieved statistically significant and clinically meaningful improvements across both co-primary endpoints — histologic remission and the frequency and severity of difficulty swallowing — at Week 24. The benefits were sustained through Week 52, while the safety profile remained generally consistent with TEZSPIRE’s currently approved indications.

The Phase 3 trial enrolled 368 adults and adolescents with symptomatic, active EoE and compared two TEZSPIRE doses with placebo. Full results will be presented at an upcoming medical meeting and submitted to regulatory authorities.

The results are strategically important because EoE would represent a third epithelial-driven inflammatory disease in which TEZSPIRE has demonstrated efficacy. The drug is already approved for severe asthma and inadequately controlled chronic rhinosinusitis with nasal polyps in several major markets.

💬

Global Finance News 08-27-26

Amgen Stock Rises 2.7% as Argus Raises Price Target and Morgan Stanley Reiterates Overweight

Amgen (NASDAQ: AMGN) shares are up about 2.7% following positive analyst actions from Argus and Morgan Stanley, adding to bullish sentiment around the biotechnology company.

Argus analyst Jasper Hellweg raised the firm's price target on Amgen to $460 from $375 while maintaining a Buy rating. The new target represents roughly 5% upside from the stock's current price of $436.60.

Morgan Stanley analyst Terence Flynn also reiterated an Overweight rating on Amgen. Although the displayed $362 price target is below the current share price, the continued Overweight recommendation provides another positive signal on the company's broader outlook.

Amgen is one of the world's largest biotechnology companies, with a diversified portfolio spanning oncology, cardiovascular disease, inflammation and rare diseases. Its scale, established product portfolio and pipeline provide a relatively defensive position within the biotech sector, while newer products and pipeline development offer additional growth opportunities.

The 2.7% gain appears supported by the combination of Argus' substantial price-target increase and Morgan Stanley's reiterated bullish rating, with Argus' move particularly notable given the increase from $375 to $460.

💬

Global Finance News 08-19-26

Amgen Stock Edges Higher After Strong Q2 Earnings as Growth Portfolio Drives Double-Digit Revenue Increase

Amgen (NASDAQ: AMGN) shares rose about 1% in after-hours trading on Tuesday after the biotechnology company reported stronger second-quarter results, supported by broad-based product growth, expanding profitability, and solid cash generation.

Second-quarter revenue increased 10% year over year to $10.1 billion, while product sales climbed 9% on higher volumes. GAAP earnings per share surged 65% to $4.37, and non-GAAP EPS increased 4% to $6.29, exceeding the prior year's performance despite higher research and operating expenses. The company also generated $3.5 billion in free cash flow during the quarter, nearly doubling from a year earlier.

Growth was driven by Amgen's expanding portfolio, with six key growth products collectively rising 26% year over year and accounting for nearly 70% of total product sales. Twenty-two products delivered double-digit sales growth, while seventeen products are now generating annualized sales exceeding $1 billion.

Several blockbuster medicines posted particularly strong results. Repatha sales jumped 37%, EVENITY climbed 38%, TEZSPIRE gained 42%, and rare disease therapies continued to perform well, led by UPLIZNA, whose sales surged 90%. Oncology products also remained a key growth driver, with IMDELLTRA sales more than doubling, while BLINCYTO, Nplate, Vectibix and LUMAKRAS all delivered double-digit growth.

Not every product performed as strongly. Sales of Prolia and XGEVA declined sharply as biosimilar competition intensified, while Otezla, Enbrel and Kyprolis also posted lower sales.

Looking ahead, Amgen reaffirmed its full-year 2026 outlook, expecting revenue between $38.2 billion and $39.4 billion and non-GAAP earnings per share of $22.30 to $23.50. The company also continues advancing its late-stage pipeline, including obesity candidate MariTide and several Phase 3 programs, while expanding existing medicines into new indications.

Investors appeared encouraged by the combination of double-digit revenue growth, continued strength across Amgen's newer products, improving cash generation, and management's confidence in sustaining long-term growth despite increasing biosimilar competition across parts of its mature portfolio.

💬

WS Investor 08-04-26

09-08-26The Investor

NASDAQ:MSFT

IBM and Microsoft Launch Imagine Enterprise Agentic AI Platform for Industry-Specific Workflows

IBM (NYSE: IBM) and Microsoft (NASDAQ: MSFT) launched Imagine Enterprise, a new agentic AI platform designed to help companies build, deploy and govern AI agents for industry-specific business processes.

The platform combines IBM Consulting’s library of more than 6,000 pre-built AI agents and assets with Microsoft’s AI, cloud, data, security and productivity technologies. The companies are also offering forward-deployed engineering support for qualifying enterprise engagements to help customers move AI projects from experimentation into production.

Imagine Enterprise is designed to integrate with existing enterprise data, processes and systems rather than requiring companies to replace their current technology stack. Governance, observability, identity, security and compliance controls are built into the platform, with an initial focus on regulated industries.

Microsoft technologies including Foundry, GitHub Copilot, Copilot Studio, Fabric, Microsoft 365, Entra, Purview, Defender and Azure provide the underlying AI, data, identity and cloud foundation. IBM Consulting contributes its Advantage platform, including Process Studio, Context Studio and Advantage Core, to help customers design and manage tailored AI agents.

Financial technology company SEI is among the organizations exploring the platform, using IBM Consulting and Microsoft technologies to support enterprise transformation and evaluate agentic AI across internal and client-facing processes.

Imagine Enterprise initially includes industry frameworks for financial services, insurance and retail, with IBM and Microsoft planning potential expansion into manufacturing, energy, public sector, mobility and other industries.

The launch deepens the longstanding IBM-Microsoft partnership and reflects both companies’ push to move enterprise AI beyond standalone productivity tools toward coordinated AI agents capable of executing complex, industry-specific workflows.

💬

WS Investor 11-10-26

Microsoft Posts Strong FY27 Q1 as Azure Growth Accelerates and Cloud Backlog Surges

Microsoft (NASDAQ: MSFT) reported a strong fiscal first-quarter 2027, with revenue rising 19% year over year to $92.3 billion and results exceeding management’s expectations across revenue, operating income and earnings per share.

Operating income increased 21% to $45.9 billion, while GAAP net income rose 32% to $36.6 billion. Non-GAAP net income, which excludes the impact of Microsoft’s OpenAI investments, increased 18% to $36.4 billion. Adjusted diluted EPS rose 18% to $4.89.

Cloud and AI infrastructure remained the primary growth engines. Microsoft Cloud revenue jumped 30% to $63.9 billion, while Azure revenue increased 48%. Commercial remaining performance obligation surged 73% to $677 billion, providing substantial visibility into future contracted revenue.

Microsoft 365 commercial cloud revenue grew 18% on an adjusted basis, while consumer cloud revenue rose 17%. Search and advertising revenue excluding traffic acquisition costs increased 12%.

Consumer hardware remained the main weak area. Windows OEM and Devices revenue declined 22%, while Xbox content and services revenue fell 2%. Overall Devices and Consumer revenue decreased 3% to $15.5 billion.

The quarter reinforces Microsoft’s position as a major beneficiary of enterprise AI and cloud spending, with accelerating Azure growth and a rapidly expanding backlog outweighing continued weakness in devices and gaming. Microsoft returned $10.2 billion to shareholders through dividends and share repurchases during the quarter.

💬

Global Finance News 11-01-26

Microsoft, Marvell and Utimaco Launch Cloud-Scale Payment Security Platform

Microsoft, Marvell Technology and Utimaco introduced Azure Payment HSM v2, a new cloud-native payment security platform designed for banks, payment processors and other financial institutions operating regulated payment workloads.

The service combines Marvell’s LiquidSecurity hardware security modules, Utimaco’s Atalla Payments Module software and Microsoft Azure into a fully managed offering. It is designed to help customers secure payment transactions, protect cryptographic keys and meet PCI security, audit and compliance requirements without deploying or managing their own physical HSM infrastructure.

The platform targets growing demand for scalable payment infrastructure as transaction volumes, fraud risks and regulatory requirements increase. Marvell provides the cloud-scale hardware security layer, Utimaco supplies payment-focused cryptographic software, and Azure delivers the solution as a managed cloud service.

Azure Payment HSM v2 is available in public preview beginning September 17 in the Western U.S. and Western Europe.

For Marvell, the partnership broadens the use of its security hardware beyond traditional data-center infrastructure and into cloud-based financial services, an area where demand for secure, high-throughput payment processing continues to expand.

💬

The Investor 09-17-26

Microsoft Corp. on Tuesday announced that its board of directors declared a quarterly dividend of $0.98 per share, reflecting a 7 cent or 8% increase over the previous quarter’s dividend. The dividend is payable Dec. 10, 2026, to shareholders of record on Nov. 19, 2026. The ex-dividend date will be Nov. 19, 2026.

The Board of Directors of JPMorgan Chase & Co. (NYSE: JPM) declared a quarterly dividend of $1.65 per share on the outstanding shares of the common stock of JPMorganChase, an increase from the prior quarterly dividend of $1.50 per share. The dividend is payable on October 31, 2026, to stockholders of record at the close of business on October 6, 2026.

💬

WS Investor 09-16-26

Microsoft Stock Jumps 8.3% as Azure and AI Growth Power Strong Q4 Earnings

Microsoft shares surged 8.3% in premarket trading on Thursday after the company reported stronger-than-expected fiscal fourth-quarter results, driven by accelerating Azure growth and continued demand for artificial intelligence products.

Revenue rose 18% year-over-year to $90.0 billion, while operating income increased 18% to $40.6 billion. GAAP net income climbed 31% to $35.8 billion, and diluted earnings per share increased 32% to $4.81. On a non-GAAP basis, Microsoft earned $4.74 per share, up 23%.

## Azure Growth Accelerates

The strongest part of the report came from Microsoft’s cloud operations. Microsoft Cloud revenue increased 27% to $59.3 billion, while Intelligent Cloud revenue rose 32% to $39.3 billion.

Azure and other cloud services revenue jumped 43%, highlighting continued demand for cloud infrastructure and AI computing capacity. Microsoft also said annual Azure revenue surpassed $100 billion for the first time.

Commercial remaining performance obligations surged 84% to $678 billion, providing investors with greater visibility into future contracted revenue.

AI adoption also continued to expand. Microsoft 365 Copilot reached more than 30 million paid seats, strengthening the company’s position as one of the leading beneficiaries of enterprise AI spending.

## Consumer and Gaming Businesses Remain Weak

Growth was less consistent across Microsoft’s consumer businesses. More Personal Computing revenue declined 4% to $12.9 billion, as Windows OEM and Devices revenue fell 7% and Xbox content and services revenue dropped 10%.

However, investors largely overlooked those declines as the performance of Azure, Microsoft Cloud and AI-related products reinforced confidence in the company’s long-term growth outlook.

Microsoft returned $10.2 billion to shareholders through dividends and share repurchases during the quarter.

## What to Watch

The sharp premarket gain reflects strong investor confidence in Microsoft’s ability to convert heavy AI investment into revenue growth. Attention will now turn to management’s fiscal 2027 guidance, capital expenditure plans and comments on whether Azure growth can remain above 40% as demand for AI infrastructure continues to rise.

💬

European Investor 07-30-26

Microsoft Receives Fresh Wall Street Support as Analysts Reaffirm Bullish Ratings

Microsoft (MSFT) received another vote of confidence from Wall Street as both Cantor Fitzgerald and TD Cowen reiterated positive ratings on the stock, maintaining Overweight and Buy recommendations, respectively.

The analyst updates come despite Microsoft's shares trading roughly 15% below their highs reached last year. With price targets of $502 and $540, both firms continue to see substantial upside from the current share price near $427, reflecting confidence in the company's long-term growth trajectory.

Analysts remain particularly optimistic about Microsoft's leadership in artificial intelligence, cloud computing, and enterprise software. The company continues to benefit from strong demand for Azure cloud services, expanding adoption of AI-powered Copilot products, and its strategic partnership with OpenAI.

While some technology stocks have recently faced profit-taking pressure, Microsoft's diversified business model and strong cash generation continue to make it one of Wall Street's favorite large-cap technology names. The reaffirmed ratings suggest analysts believe the recent pullback from previous highs has not altered the company's long-term investment case.

With AI investment continuing to accelerate across industries, analysts expect Microsoft to remain one of the primary beneficiaries of the ongoing digital transformation and artificial intelligence spending cycle. The latest rating reiterations reinforce the view that Wall Street remains highly confident in Microsoft's ability to deliver sustained earnings growth in the years ahead.

💬

WS Investor 06-04-26

Microsoft Reports 17% Revenue Growth in Fiscal Q2 2026, Cloud Tops $50 Billion

Microsoft posted revenues of $81.3 billion for its fiscal second quarter ended December 31, 2025, up 17% year over year. Operating income rose 21% to $38.3 billion, while GAAP net income jumped 60% to $38.5 billion, partly reflecting gains from its OpenAI investment. On a non-GAAP basis, net income grew 23% to $30.9 billion. Diluted EPS came in at $5.16 on a GAAP basis. Microsoft Cloud revenue crossed $50 billion for the quarter, underscoring strong demand across the company's portfolio. CEO Satya Nadella noted that Microsoft's AI business has already grown larger than some of its most established franchises.

Source: Microsoft Corp. Earnings Release, January 28, 2026

💬

Global Finance News 04-29-26

Microsoft Corp. on Tuesday announced that its board of directors declared a quarterly dividend of $0.91 per share. The dividend is payable June 11, 2026, to shareholders of record on May 21, 2026.

💬

The Investor 03-11-26

Tech stocks today: Nvidia stock rises as guidance signals AI boom alive and well

All eyes are on Nvidia's fourth quarter results, due after the closing bell on Wednesday, as AI concerns continue to grip markets.

(finance.yahoo.com)

💬

WS News 02-26-26

CrowdStrike (NASDAQ: CRWD) and Microsoft (NASDAQ: MSFT) have expanded their strategic alliance to make the CrowdStrike Falcon platform available on Microsoft Marketplace, allowing customers to purchase it using their existing Microsoft Azure Consumption Commitment funds.

The move enables organizations to apply pre-committed Azure cloud spending toward Falcon’s AI-native cybersecurity platform, simplifying procurement, consolidating billing, and accelerating deployment across endpoints, cloud workloads, identity, AI, and data environments.

By aligning security purchases with cloud budgets, the partnership reduces procurement friction and helps customers optimize cloud spend while strengthening security posture. Industry analysts note that transacting Falcon through Azure Marketplace can accelerate deal velocity and streamline the path from agreement to deployment.

The Falcon platform is immediately available via Microsoft Marketplace with full Azure Consumption Commitment eligibility.

Source: Business Wire

💬

Global Finance News 02-18-26

11-03-26Global Finance News

10-26-26Global Finance News

10-15-26The Investor

10-13-26The Investor

10-02-26WS News

NYSE:IBM

💬

WS Investor 11-10-26

IBM Unveils Most Advanced Quantum System in Illinois as Chicago Quantum Hub Expands

IBM (NYSE: IBM) unveiled its first quantum computer in Illinois, deploying an IBM Quantum System Two at the University of Chicago’s Hyde Park Labs as part of the state’s expanding quantum technology ecosystem.

The system is powered by IBM Quantum Nighthawk, which IBM describes as its most powerful quantum chip to date. It will initially operate at Hyde Park Labs before eventually moving to the Illinois Quantum and Microelectronics Park, where it will anchor the National Quantum Algorithm Center.

IBM said the system will support research and commercial development across areas including drug discovery, power-grid optimization, high-energy physics and distributed quantum computing. Current collaborations involve organizations such as Deloitte, AbbVie, EPRI, Fermilab, Northwestern University and the University of Illinois Urbana-Champaign.

The deployment also deepens IBM’s strategic presence in Chicago. The company previously announced plans for a FutureNow Chicago center at the quantum park, expected to support 750 jobs across AI, cybersecurity, data science and quantum computing.

For IBM, the installation strengthens its leadership position in quantum infrastructure while expanding the ecosystem around real-world quantum applications and enterprise research partnerships.

💬

Global Finance News 11-07-26

IBM and SAP Expand Cloud ERP Offering to Help Businesses Build AI-Ready Operations

IBM (NYSE: IBM) announced IBM Ready for SAP Solutions, a new offering designed to help midsize and fast-growing companies modernize ERP systems, unify enterprise data and establish a stronger foundation for future AI deployments.

The solution combines IBM’s industry expertise, fit-to-standard delivery approach and IBM Consulting Advantage, its AI-powered consulting platform, with SAP Cloud ERP. IBM said the offering is intended to shorten transformation timelines while helping companies standardize operations and prepare data and business processes for broader AI use.

Volumetric Building Companies is one early customer. The modular construction company completed an SAP Cloud ERP transformation with IBM in three months and reduced operational cycle times by 50% across purchasing, manufacturing and inventory processes.

Second Nature Brands also used the offering to integrate the Voortman Bakery business following an acquisition, creating a common enterprise platform across the combined organization.

IBM said the two deployments illustrate different use cases for the platform: operational efficiency on one side and post-acquisition integration on the other. Both are aimed at creating a more connected digital core that can support automation and AI at scale.

The launch reflects growing demand for ERP modernization as companies seek to connect data, processes and AI systems more effectively. IBM cited research showing that 68% of enterprises consider accelerating ERP modernization important for improving efficiency and competitiveness.

IBM Ready for SAP Solutions is currently available in selected countries and industries, with broader global expansion planned.

💬

Global Finance News 10-07-26

Zscaler (NASDAQ: ZS) announced a collaboration with IBM and Red Hat aimed at protecting private applications during the critical period between vulnerability disclosure and patch deployment.

The partnership combines Zscaler’s Autonomous Application Shield with Lightwell from IBM and Red Hat, allowing organizations to block exploit attempts in real time while validated software fixes are prepared and deployed. Zscaler said the approach is designed to address a growing cybersecurity challenge as AI accelerates the speed at which newly disclosed vulnerabilities can be exploited.

Operating through the Zscaler Zero Trust Exchange, the system continuously assesses private applications for exposure and applies application-specific protections when new vulnerabilities emerge. Lightwell then provides validated source-level remediation for affected open-source software.

The companies said the integrated approach will support exposure discovery, machine-speed threat response and targeted remediation, reducing reliance on traditional patching cycles alone.

Zscaler’s Autonomous Application Shield is currently available through an Early Access Program.

💬

Global Finance News 10-06-26

IBM Adds Self-Hosted Deployment for Bob to Expand Enterprise AI Sovereignty

IBM introduced a self-hosted deployment option for IBM Bob, its agentic software development platform, allowing enterprises to run AI-powered development and modernization tools inside on-premises, private-cloud, sovereign-cloud and air-gapped environments.

The new deployment model is aimed at organizations handling sensitive source code, regulated data or mission-critical systems that may not be able to use public AI platforms because of security, compliance and data-residency requirements.

With the self-hosted version, enterprises can keep code, application context and data inside infrastructure they control while still using Bob for software development and modernization. Organizations can run supported licensed models on premises or connect Bob to external model services through hybrid configurations.

IBM said the approach allows customers to “bring AI to the data” rather than moving sensitive data to external AI services. The company is targeting regulated industries and organizations with strict governance requirements, including financial services, healthcare, telecommunications and government.

The launch reflects growing demand for sovereign and hybrid AI infrastructure as enterprises seek more control over where AI workloads run, what data they access and how they are governed.

💬

WS Investor 10-01-26

IBM Backs NVIDIA Open Agent Safety Platform to Strengthen Enterprise AI Agent Security

IBM is supporting NVIDIA’s new Open Agent Safety Platform, an open software platform and reference design aimed at securing and governing AI agents as they take on more autonomous work across enterprise environments.

IBM said its contribution spans agent identity, credentials, infrastructure, storage and hybrid cloud. IBM Agent Identity and HashiCorp Vault are integrating with NVIDIA OpenShell to give agents verified identities and tightly controlled access, while IBM Identity Protection is designed to help organizations discover and monitor agents across their environments.

At the infrastructure level, IBM Storage is integrating NVIDIA BlueField-4 into IBM Fusion, while Red Hat OpenShift will support governed agent deployments across hybrid cloud environments. Red Hat is also working with NVIDIA to integrate BlueField and OpenShell for zero-trust security, runtime isolation and real-time threat detection.

NVIDIA’s approach places agents inside a policy-governed runtime and uses its Sentry framework and BlueField hardware to enforce access policies, verify agent identity and monitor behavior. IBM said the goal is to make agent actions attributable, least-privileged and auditable, even if the underlying workload is compromised.

The broader focus is shifting from what AI models can do to what enterprises can safely allow autonomous agents to do. IBM also joined NVIDIA as a founding member of the Open Secure AI Alliance, which is governed by the Linux Foundation.

💬

European Investor 09-28-26

IBM Acquires Logiq Consulting to Expand UK Cybersecurity and Secure Digital Transformation Capabilities

IBM (NYSE: IBM) acquired Logiq Consulting, a UK cybersecurity consultancy with expertise across defence, critical national infrastructure, government and other highly regulated sectors. The deal expands IBM Consulting’s cybersecurity and sovereign technology capabilities in the UK.

Logiq Consulting brings capabilities in cybersecurity assurance, Secure by Design, secure systems engineering, digital transformation and managed services. IBM said the acquisition will complement its existing SiXworks business and support its broader hybrid cloud, AI and digital sovereignty strategy, particularly for clients that need tighter control over sensitive data and technology environments.

The transaction also adds Logiq’s DISX platform, a managed sovereign collaboration system used to help government suppliers securely exchange sensitive information with UK government and defence organizations. IBM said the acquisition should strengthen its ability to help clients manage cyber risk, protect critical services and adopt AI securely.

💬

WS Investor 09-24-26

IBM’s Anderon Finalizes $1 Billion U.S. CHIPS Award for Quantum Foundry

IBM (NYSE: IBM) subsidiary Anderon has finalized a $1 billion CHIPS and Science Act award with the U.S. Department of Commerce to accelerate research and development for quantum wafer manufacturing in the United States. The agreement follows the $1 billion proposed award announced in May.

Anderon operates a 300-millimeter pure-play quantum wafer foundry in Albany, New York, supported by an additional $1 billion investment from IBM. The facility is designed to manufacture specialized wafers for superconducting qubit arrays, quantum input/output signaling and readout components, with plans to support additional quantum technologies over time.

The company has already begun running its first quantum wafers through the facility, marking an early step toward production-scale manufacturing. The foundry is intended to serve IBM as well as other quantum technology companies, potentially expanding the domestic supply chain for quantum hardware.

The investment also supports IBM’s broader quantum strategy. IBM has committed more than $10 billion to quantum computing over five years and is working toward large-scale fault-tolerant quantum systems, making scalable wafer manufacturing an important part of its long-term technology roadmap.

💬

WS Investor 09-16-26

IBM and Lockheed Martin Launch Swiss Quantum Innovation Hub at ETH Zurich

IBM and Lockheed Martin have established a new quantum innovation hub at ETH Zurich that will host Switzerland’s first IBM Quantum System Two, expanding access to advanced quantum computing for Swiss universities, industries and startups.

The system will be installed at the Swiss National Supercomputing Centre in Lugano and operated by IBM. It will use IBM’s Quantum Nighthawk processor, while ETH Zurich will provide expertise and resources to support research, workforce development and new industrial applications. Deployment is expected by the end of 2026.

Organizations participating in the hub will initially gain access to IBM’s existing quantum computers through the cloud before receiving access to the dedicated Swiss system. Potential applications include chemistry, materials science, optimization and financial services.

The initiative also expands the existing IBM-Lockheed Martin partnership. The companies plan joint research projects exploring quantum sensing for navigation and the use of advanced technologies to improve additive manufacturing of metallic alloys, with potential applications in aerospace and defense.

💬

The Investor 09-10-26

IBM Completes HRL Laboratories Acquisition to Strengthen Quantum Computing Roadmap

IBM (NYSE: IBM) has completed its acquisition of HRL Laboratories, bringing additional expertise in quantum computing, quantum sensing, materials science and advanced semiconductor technologies into IBM’s expanding quantum ecosystem.

The deal combines IBM’s leadership in superconducting quantum computing with HRL’s expertise in silicon-spin qubits, giving IBM exposure to complementary approaches to quantum hardware as it works toward large-scale, fault-tolerant quantum systems.

HRL Adds New Capabilities to IBM’s Quantum Platform

HRL Laboratories brings research capabilities spanning silicon-spin qubits, quantum sensing, quantum materials, cryogenics, control electronics, advanced packaging and interconnect technologies.

The silicon-spin expertise is particularly notable because IBM’s current quantum systems are primarily based on superconducting qubits. Adding HRL therefore broadens IBM’s technical capabilities rather than simply expanding its existing architecture.

HRL’s work in cryogenics, electronics and packaging could also contribute to solving some of the engineering challenges involved in scaling quantum computers from experimental systems toward commercially useful machines.

Acquisition Supports IBM’s Fault-Tolerant Quantum Roadmap

The transaction comes as IBM pushes toward its planned IBM Quantum Starling system, a fault-tolerant quantum computer targeted for 2029. IBM expects Starling to perform 100 million quantum operations, representing a major increase in computational capability compared with current systems.

Starling is expected to be followed by Blue Jay, IBM’s next-generation fault-tolerant system targeted for the mid-2030s.

HRL’s technology could support that roadmap across several layers of the quantum stack, particularly hardware design, materials, control systems and manufacturing.

The acquisition also complements IBM’s investment in quantum manufacturing. HRL’s silicon-based quantum technologies could eventually work alongside Anderon, IBM’s pure-play quantum wafer foundry, potentially allowing IBM to accelerate development and manufacturing across multiple quantum-computing architectures.

Why the Acquisition Matters for IBM

The deal reinforces IBM’s position as one of the major companies pursuing commercially viable quantum computing. More importantly, IBM is expanding beyond a single technological approach by combining its superconducting-qubit expertise with HRL’s silicon-spin capabilities.

That diversification could become strategically important because the industry has not yet established which qubit architecture — or combination of architectures — will ultimately provide the best path toward scalable fault-tolerant quantum computing.

The acquisition also preserves important industrial relationships. Boeing and General Motors, HRL’s former owners, will continue working with IBM and HRL on quantum applications and advanced technology development.

For IBM, the transaction is therefore more than an expansion of its research organization. It adds complementary quantum technologies, specialized engineering expertise and industrial partnerships as the company works toward its ambitious 2029 fault-tolerant quantum computing target.

💬

The Investor 08-26-26

07-14-26WS News

07-09-26WS News

06-23-26WS News

06-02-26European Investor

05-24-26The Investor

NYSE:QBTS

D-Wave Falls 9% as Quarterly Bookings Drop and Losses Widen Despite Strong Backlog Growth

D-Wave Quantum (NASDAQ: QBTS) shares fell about 9% on Tuesday after the company reported weaker quarterly bookings, sharply higher operating expenses and a wider adjusted EBITDA loss, despite strong year-to-date demand indicators.

Third-quarter revenue increased 21% year over year to $4.5 million, supported by higher professional services and quantum-computing-as-a-service revenue. However, quarterly bookings fell 19% to $1.9 million.

Longer-term demand metrics remained much stronger. Nine-month bookings surged 611% to $37.4 million, while remaining performance obligations climbed 1,221% year over year to $38.3 million. About 59% of that backlog is expected to convert into revenue within the next 12 months.

Profitability metrics weakened. GAAP gross margin fell to 52.9% from 71.4%, while adjusted gross margin declined to 63.6%. GAAP operating expenses jumped 84% to $55.9 million, and the adjusted EBITDA loss widened 83% to $37.7 million.

D-Wave ended the quarter with $503.4 million in cash and marketable securities and also secured access to up to $100 million of U.S. CHIPS Act funding, subject to milestones.

The 9% decline appears to reflect investor concern over lower quarterly bookings, margin compression and accelerating cash burn, outweighing the strong growth in backlog, year-to-date bookings and government-supported funding visibility.

💬

WS Investor 11-10-26

D-Wave Drops 12% as Revenue Collapses and Losses Widen Despite Booking Surge

May 12, 2026 | NYSE: QBTS

D-Wave is the session's sharpest earnings-driven decliner today, falling 12% as investors focus on the stark gap between the company's ambitious narrative and its current financial reality.

The headline numbers are difficult to look past. Revenue for the first quarter came in at just $2.9 million, down 81% year-on-year. The comparison is somewhat distorted — Q1 2025 included a one-time $12.6 million system sale — but even accounting for that, underlying revenue generation remains extremely thin for a company with a market cap that prices in significant future success. Adjusted EBITDA loss widened to $32.8 million from $6.1 million a year ago, and net loss grew to $18.4 million as operating expenses surged 125% to $56.5 million, driven by the Quantum Circuits acquisition costs, expanded headcount, and higher R&D spending.

The bull case rests entirely on bookings, which were genuinely impressive. D-Wave recorded $33.4 million in bookings for the quarter, up nearly 2,000% year-on-year, anchored by a $20 million system purchase from Florida Atlantic University and a $10 million two-year QCaaS agreement with a Fortune 100 company. Remaining performance obligations jumped 563% to $42.4 million. These are real commercial signals, but the revenue from the FAU system sale will only be recognized in future quarters, leaving a wide chasm between bookings momentum and reported financials today.

The acquisition of Quantum Circuits adds strategic depth — dual-rail gate-model technology that management believes is unmatched in the industry — but it also adds cost and complexity at a stage when the company is already burning cash rapidly. The roadmap to error-corrected gate-model systems extends to 2032, a long runway to ask investors to finance.

With $588 million in cash on hand, D-Wave has the runway to execute. But today's market is telling the company it needs to start converting its booking momentum into recognized revenue before the story can sustain its valuation.

💬

WS Investor 05-12-26

D-Wave Quantum Inc. announced that Florida Atlantic University has signed a $20 million agreement to purchase and install an Advantage2 annealing quantum computer at FAU’s Boca Raton campus.

The system, expected to be deployed later in 2026, will form the core of a broader collaboration aimed at advancing quantum education, research, and applied innovation in Florida. The partnership may include the creation of a D-Wave Quantum Applications Academy at FAU, along with research, training, and workforce development initiatives. The state of Florida and the city of Boca Raton are also providing job growth and training incentives to support the expansion of quantum-related talent and operations.

D-Wave separately announced plans to establish its new corporate headquarters at the Boca Raton Innovation Center, strengthening Florida’s role as an emerging hub for quantum computing and applied quantum technologies.

💬

European Investor 01-27-26

D-Wave Quantum Inc. announced a $10 million, two-year enterprise Quantum Computing as a Service (QCaaS) agreement with a Fortune 100 company, marking a notable step in the commercial adoption of quantum computing. Under the deal, the partners will collaborate to develop and deploy multiple quantum-powered applications using D-Wave’s annealing and gate-model platforms.

D-Wave said the agreement underscores growing enterprise demand for production-grade quantum solutions and highlights its position as the only provider offering dual-platform quantum systems available both on-premises and via cloud services. The company added that the partnership reflects increasing confidence among large corporations in applying quantum technology to solve complex, real-world computational challenges.

💬

European Investor 01-27-26

D-Wave Quantum announced an agreement to acquire Quantum Circuits for $550 million, comprising $300 million in D-Wave common stock and $250 million in cash. The transaction is expected to close in late January 2026, subject to regulatory approvals and NYSE listing clearance.

The acquisition combines D-Wave’s commercial annealing quantum computing platform with Quantum Circuits’ error-corrected superconducting gate-model technology, positioning the company to address the full quantum computing market. D-Wave plans to introduce its first commercially available superconducting gate-model system in 2026, alongside its existing annealing systems, accelerating the path toward scalable, fault-tolerant quantum computing.

Quantum Circuits’ dual-rail qubit architecture, which integrates built-in error detection, is expected to reduce the number of physical qubits required for logical qubits. As part of the deal, Quantum Circuits’ research team, including Yale professor and co-founder Rob Schoelkopf, will establish a D-Wave research and development center in New Haven, Connecticut, strengthening the combined company’s superconducting quantum research capabilities.

💬

The Investor 01-08-26

share news and insights

💬

Global Finance News 01-24-25

06-02-26European Investor

04-23-26WS News

04-07-26European Investor

02-10-26WS Investor

10-14-25WS News

US

💬

WS Investor 11-10-26

U.S. Inflation Expectations Hold at 3.9% as Atlanta Fed Raises Q4 Growth Estimate

U.S. one-year consumer inflation expectations were unchanged at 3.9% in October, according to the New York Federal Reserve, slightly above the 3.8% forecast.

Separately, the Atlanta Fed’s GDPNow model raised its estimate for fourth-quarter economic growth to 3.5% from 3.4%, also slightly above the 3.4% consensus estimate.

The combination points to a U.S. economy that remains relatively resilient while near-term inflation expectations stay elevated.

For Federal Reserve policy, the data are modestly hawkish: stronger growth estimates and inflation expectations above forecast could reduce the urgency for additional near-term rate cuts.

💬

WS News 11-09-26

U.S. Consumer Sentiment Improves in November as Inflation Expectations Ease

U.S. consumer sentiment improved more than expected in November, while both short- and long-term inflation expectations declined.

The University of Michigan Consumer Sentiment Index rose to 51.0 from 48.0, beating the 48.1 forecast. Consumer expectations also improved to 50.9 from 48.8, above expectations of 49.5.

One-year inflation expectations fell to 4.3% from 4.7%, below the 4.6% forecast. Five-year inflation expectations eased to 3.4% from 3.5%, also slightly better than expected.

The combination of stronger sentiment and softer inflation expectations is broadly constructive, suggesting consumers became somewhat less pessimistic while inflation concerns moderated. For monetary policy, the decline in inflation expectations partly offsets the earlier strength in payrolls and wages, leaving the Federal Reserve with mixed signals on the inflation outlook.

💬

WS Investor 11-06-26

U.S. Payrolls Surge by 165,000 in October as Unemployment Falls to 4.1%

U.S. nonfarm payrolls increased by 165,000 in October, far above the 65,000 forecast and up from 60,000 previously, signaling substantially stronger-than-expected job creation.

The unemployment rate fell to 4.1%, compared with expectations for it to remain at 4.2%.

Average hourly earnings also came in stronger than expected, rising 0.4% month over month versus the 0.3% forecast and previous increase.

Taken together, the data point to a resilient labor market with stronger hiring, lower unemployment and firm wage growth. The report could reduce expectations for near-term Federal Reserve rate cuts, as persistent labor-market strength and wage pressures may keep inflation risks elevated.

💬

WS Investor 11-06-26

💬

The Investor 11-05-26

U.S. Trade Deficit Narrows in September as Exports Rise Faster Than Imports

The U.S. trade deficit narrowed to $105.0 billion in September, slightly better than the $107.9 billion forecast and down from $105.7 billion in the previous month.

Exports increased to $321.5 billion from $315.7 billion, a rise of $5.8 billion. Imports also increased, reaching $426.6 billion from $421.4 billion, but the $5.2 billion gain was smaller than the increase in exports.

The data therefore point to a modest improvement in the U.S. external trade position, with export growth outpacing import growth during the month.

💬

WS Investor 11-04-26

💬

WS Investor 11-04-26

Gold and Bitcoin Rally as Democratic Midterm Sweep Reshapes U.S. Market Outlook

Gold and Bitcoin moved sharply higher on Wednesday while market volatility declined as investors digested a sweeping Democratic victory in the U.S. midterm elections that handed the party control of both the House and Senate.

Democrats captured both chambers of Congress in the November 3 elections, creating a divided government with Republican President Donald Trump and raising expectations that parts of the administration’s legislative agenda could face greater resistance during the second half of his term.

Gold futures jumped 2.9% to about $4,055 an ounce in early trading, rebounding strongly above the $4,000 level. The move coincided with a weaker U.S. dollar and a post-election rally in Treasuries. The move is particularly notable because gold had struggled as a traditional safe haven in the weeks leading into the election. The post-election rebound suggests that falling yields, dollar weakness and renewed political uncertainty may be providing support for the non-yielding metal.

Bitcoin also recovered strongly, rising 1.6% to around $78,200 after briefly falling below $76,000 overnight. The rebound came as broader risk sentiment stabilized following the election result. Lower interest-rate expectations can provide support for speculative assets such as cryptocurrencies, although Bitcoin has also been dealing with crypto-specific volatility following recent market disruptions.

Treasury markets showed an important shift around the election. The 10-year yield had closed November 3 at about 4.95%, up 1.2% on the day, but yields subsequently moved lower as investors assessed the implications of Democratic congressional control.

Meanwhile, the CBOE Volatility Index fell 8.2% to 19.13. The decline in the VIX suggests that the removal of election uncertainty outweighed immediate concerns about political confrontation in Washington.

The market response therefore presents an unusual combination: gold is benefiting from lower yields and political uncertainty, Bitcoin is rebounding alongside improving risk appetite, and volatility is declining as investors gain greater clarity over the political landscape.

The Democratic sweep could still create significant sector-level consequences. With Congress now positioned to challenge Trump administration policies and increase oversight, markets are likely to focus increasingly on fiscal spending, tariffs, energy policy and regulation of the rapidly expanding AI and data-center industries.

💬

European Investor 11-04-26

U.S. Job Openings and Factory Orders Beat Forecasts in September

U.S. economic data came in stronger than expected in September, with both job openings and factory orders exceeding market forecasts.

JOLTS job openings rose to 7.523 million, well above the 7.150 million forecast and up from 7.190 million previously. The stronger reading suggests labor demand remained relatively resilient despite signs of gradual cooling elsewhere in the employment market.

Factory orders increased 1.8% month over month, also beating the 1.2% forecast and accelerating sharply from the previous 0.3% increase.

The combination of stronger labor demand and faster factory-order growth points to firmer underlying economic activity than expected. For financial markets, the data may modestly reduce expectations for aggressive Federal Reserve easing, particularly if upcoming employment and inflation indicators also remain strong.

💬

The Investor 11-03-26

💬

European Investor 11-02-26

11-08-26WS News

11-06-26WS Investor

11-05-26The Investor

11-04-26WS Investor

10-19-26WS News

NASDAQ:FANG

Diamondback Energy and KKR to Acquire Full Ownership of Deep Blue Midland Basin

Diamondback Energy (NASDAQ: FANG) and KKR agreed to jointly acquire Five Point Infrastructure’s 70% stake in Deep Blue Midland Basin, giving the two companies full ownership of the water infrastructure platform.

Diamondback already owns 30% of Deep Blue, which was formed in 2023 with Five Point. Following the transaction, Diamondback and KKR will jointly own 100% of the business.

Deep Blue operates an integrated water infrastructure network across the Midland Basin, providing sourcing, transportation, storage, recycling and disposal services for oil and gas operators. Diamondback said the system is critical to its own operations, which require transportation of nearly 2 million barrels of water per day.

The transaction also creates a broader infrastructure partnership between Diamondback and KKR. The companies said they see potential opportunities to expand Deep Blue beyond traditional oil and gas applications, including new technology and industrial uses in the Permian Basin.

KKR will fund its investment primarily through KKR Global Infrastructure Investors V. The transaction is expected to close in the fourth quarter of 2026, subject to regulatory approvals and customary closing conditions.

For Diamondback, the deal secures long-term control over strategically important water infrastructure supporting its Permian Basin operations, while also creating a platform for future infrastructure investment alongside KKR.

💬

WS Investor 11-10-26

Diamondback Energy Rises 1.6% Premarket as Strong Free Cash Flow and Dividend Increase Support Shares

Diamondback Energy (NASDAQ: FANG) shares rose about 1.6% in premarket trading after the company reported strong third-quarter 2026 cash generation, increased its base dividend and raised full-year production guidance.

Average oil production was 525,000 barrels per day, with total production of 1.034 million barrels of oil equivalent per day. Diamondback generated $2.6 billion of operating cash flow and $3.2 billion before working-capital changes.

Free cash flow reached $2.1 billion, while adjusted free cash flow totaled $2.2 billion against approximately $1.0 billion of cash capital expenditures. The strong cash generation supported continued shareholder returns and debt reduction.

Diamondback increased its annual base dividend by 7.3% to $4.72 per share, representing an 18% increase from a year earlier. The company also repurchased approximately $251 million of stock during the quarter and another $73 million of shares so far in the fourth quarter.

The company raised its 2026 oil production outlook to approximately 524,000 barrels per day from more than 522,000 previously and increased total production guidance to roughly 1.015 million BOE per day. Full-year capital spending guidance was also lifted slightly to $3.95 billion-$4.00 billion from approximately $3.9 billion.

Diamondback additionally acquired a 7.5% stake in the Solitude Pipeline System, strengthening its exposure to Permian natural gas infrastructure.

The 1.6% premarket gain appears to reflect the combination of strong free cash flow, higher production expectations and increased shareholder distributions. The modest increase in capital spending provides a partial offset, but the quarter demonstrates Diamondback’s ability to fund investment while simultaneously raising dividends, repurchasing shares and reducing debt.

💬

Global Finance News 11-03-26

Diamondback Energy Slips in Pre-Market Despite Strong Q1 and Raised Production Guidance

May 5, 2026

Diamondback Energy (NASDAQ: FANG) is trading about 1.68% lower in Tuesday's pre-market session, even after the Permian Basin-focused oil producer posted a solid first quarter and raised its full-year production outlook. The decline likely reflects broader oil price pressures and investor caution around rising capital expenditure guidance rather than any weakness in the underlying business.

Q1 by the Numbers

Diamondback produced an average of 521.0 thousand barrels of oil per day in the first quarter, or 979.4 thousand barrels of oil equivalent per day in total. Net cash provided by operating activities came in at $1.8 billion, while operating cash flow before working capital changes reached $2.6 billion. Cash capital expenditures for the quarter were $933 million, leaving free cash flow of $1.7 billion — a figure that underscores the capital efficiency of the company's Permian operations.

The company returned $859 million to shareholders in the quarter, roughly 50% of adjusted free cash flow, through a combination of share repurchases and its base dividend. Diamondback bought back 3.3 million shares for approximately $548 million and raised its Q1 2026 base cash dividend to $1.10 per share, a 10% increase year-over-year, implying an annualized yield of approximately 2.1% based on the May 1 closing price of $207.65.

On the balance sheet front, the company completed a cash-funded tender offer retiring approximately $777 million in principal of long-dated senior notes at 81.1 cents on the dollar — a disciplined move that reduces future interest costs. It also fully repaid the remaining $550 million on its term loan due 2027, bringing pro forma gross debt to $12.7 billion at the end of April.

Guidance Raised

Diamondback increased its full-year 2026 oil production guidance to 520 thousand barrels per day or more, up from the prior range of 500 to 510 thousand barrels per day. Total BOE production guidance was raised to 972 thousand barrels per day or more, implying approximately 5% organic year-over-year growth.

The company also raised its full-year cash capital expenditure guidance to approximately $3.90 billion, up from $3.75 billion, with the increase directed toward operated drilling and completion activity. Net lateral footage completed was also nudged higher to 6,100 to 6,500 thousand feet from 5,900 to 6,300 thousand feet previously.

For the second quarter, Diamondback guided oil production of 515 to 525 thousand barrels per day and capital expenditures of $925 million to $1.025 billion.

Why the Stock Is Down

The pre-market decline is a reminder that even strong operational results can face headwinds from macro forces. Oil prices remain a key variable for Diamondback's revenue, and any softness in crude weighs on sentiment regardless of execution quality. The upward revision to capital spending — while tied to higher production — may also give some investors pause, as it signals a heavier near-term investment cycle even as the company works to reduce debt.

That said, the fundamentals here are difficult to argue with.

Diamondback generated $1.7 billion in free cash flow in a single quarter, raised its dividend, bought back a meaningful amount of stock, and retired debt at a discount. For investors with a medium to long-term view, the raised production guidance and continued capital discipline paint a picture of a company in strong operational health.

💬

The Investor 05-05-26

Diamondback Energy, Inc. Schedules First Quarter 2026 Conference Call for May 5, 2026

💬

Global Finance News 04-03-26

Diamondback Energy disclosed that it entered into a letter agreement with SGF FANG Holdings granting SGF the option to sell up to 3 million Diamondback shares per quarter through the end of 2026 at the latest NASDAQ closing price. Under this agreement, Diamondback repurchased 2 million SGF shares on November 28, 2025 at $152.59 per share. These purchases fall under the company’s existing $8 billion buyback authorization. With this transaction, Diamondback has bought back about 2.89 million shares since September 30 for $432 million, leaving roughly $2.7 billion remaining under its repurchase program. The agreement does not restrict SGF from selling shares through other permitted methods.

💬

Global Finance News 12-01-25

Diamondback Energy posts strong Q3 results, raises full-year oil production outlook

Diamondback Energy (NASDAQ: FANG) reported robust Q3 2025 results, with average oil production reaching 503.8 thousand barrels per day (MBO/d) and total production of 942.9 thousand barrels of oil equivalent per day (MBOE/d). Operating cash flow before working capital changes totaled $2.5 billion, while free cash flow came in at $1.8 billion. Capital expenditures were $774 million. The company declared a base dividend of $1.00 per share, yielding 2.8%, and repurchased 4.3 million shares for $603 million, returning a total of $892 million to shareholders—equivalent to 50% of adjusted free cash flow.

During the quarter, subsidiary Viper Energy completed its merger with Sitio Royalties, while Diamondback divested Environmental Disposal Systems and its 27.5% stake in EPIC Crude, generating over $1.2 billion in cash proceeds with potential for $296 million in additional contingent payments. In early Q4, the company repurchased another 611 thousand shares for $87 million and $203 million in long-term notes at a discount.

Reflecting strong operational execution, Diamondback raised its 2025 oil production guidance to 495–498 MBO/d and total output to 910–920 MBOE/d, while maintaining capital expenditure guidance of $3.45–$3.55 billion. The company expects to drill up to 465 gross wells and complete as many as 520 this year, maintaining a focus on capital efficiency and shareholder returns.

💬

The Investor 11-04-25

Diamondback Energy Reports Q3 2025 Derivative Gains and Realized Prices

Diamondback Energy (NASDAQ: FANG) reported its preliminary financial highlights for the third quarter of 2025, including realized commodity prices and derivative results. The company’s unhedged realized prices averaged $64.60 per barrel of oil, $0.75 per Mcf of natural gas, and $17.28 per barrel of natural gas liquids (NGLs). With hedges included, realized prices averaged $63.70 per barrel of oil and $1.75 per Mcf of natural gas.

Diamondback anticipates a total derivative gain of $120 million for the quarter, including $60 million in non-cash gains and $60 million in net cash settlements. This includes a $15 million realized loss related to the early termination of $150 million in interest rate swaps, which the company plans to exclude from its return of capital calculation.

The company reported 288.8 million basic and diluted weighted average shares outstanding for the quarter. Diamondback noted that the figures reflect preliminary results ahead of its full quarterly earnings release.

💬

European Investor 10-09-25

Deep Blue Acquires Environmental Disposal Systems from Diamondback Energy for $750M

MIDLAND, Texas, Sept. 2, 2025 – Deep Blue Midland Basin LLC, backed by Diamondback Energy (NASDAQ: FANG) and Five Point Infrastructure, announced it will acquire Environmental Disposal Systems (EDS) from Diamondback for $750 million, nearly doubling Deep Blue’s scale as the Midland Basin’s largest independent water infrastructure platform.

As part of the deal, Diamondback renewed a 15-year water dedication to Deep Blue and will retain a 30% equity stake in the joint venture. The company will receive $675 million in upfront cash proceeds and may earn up to $200 million in performance-based payments through 2028.

Following the acquisition, Deep Blue’s system will include:
• 1.2M barrels/day of treatment and recycling capacity
• 1.6M barrels/day of water gathered
• 3.4M barrels/day of permitted disposal capacity
• 1,871 miles of interconnected pipelines
• 783,000 dedicated acres

Diamondback CEO Kaes Van’t Hof said the transaction provides “meaningful value” while keeping the company aligned as both partner and customer. Deep Blue CEO Scott Mitchell emphasized the platform’s focus on sustainable produced water recycling to support upstream development.

💬

The Investor 09-02-25

Diamondback Energy, Inc. (NASDAQ: FANG) (“Diamondback”), today announced that it plans to release second quarter 2025 financial results on August 4, 2025 after the market closes.

💬

WS Investor 06-27-25

Diamondback Energy Extends Credit Facility Maturity and Reduces Borrowing Costs

Diamondback Energy, Inc. has amended its existing credit agreement with Wells Fargo and a syndicate of lenders, extending the maturity date from June 2028 to June 2030. The sixteenth amendment to the Second Amended and Restated Credit Agreement also lowers the applicable interest rates and fees.

Borrowings will now bear interest at either a term SOFR or alternate base rate, with margins ranging from 1.000% to 1.750% for SOFR loans and 0.000% to 0.750% for base rate loans, depending on the company’s credit ratings. Commitment fees on unused amounts will range from 0.100% to 0.250%.

All other terms of the credit agreement remain unchanged. The updated terms aim to enhance Diamondback’s capital efficiency while maintaining financial flexibility.

💬

ME NEWS 06-13-25

02-19-25The Investor

Latest

Agilent Expands Hematologic Cancer Profiling Portfolio with New Pan Heme NGS Solution Agilent Technologies (NYSE: A) launched SureSelect Cancer Research

Diamondback Energy and KKR to Acquire Full Ownership of Deep Blue Midland Basin Diamondback Energy (NASDAQ: FANG) and KKR agreed

IHG Reaches 50 Open voco Hotels in Europe as Premium Brand Expansion Continues InterContinental Hotels Group (NYSE: IHG) said its

Lockheed Martin Reaches 100,000 GMLRS Rocket Milestone as Production Accelerates Lockheed Martin (NYSE: LMT) reached a major production milestone for

Uber and McDonald’s Expand Delivery and Loyalty Partnership Across 14 Markets Uber Technologies (NYSE: UBER) and McDonald’s (NYSE: MCD) expanded

ServiceNow Adds Agentic AI for Continuous Enterprise Control Monitoring ServiceNow (NYSE: NOW) introduced new agentic AI capabilities for continuous control

IBM and Microsoft Launch Imagine Enterprise Agentic AI Platform for Industry-Specific Workflows IBM (NYSE: IBM) and Microsoft (NASDAQ: MSFT) launched

Abbott Wins FDA Approval and CE Mark for UltiSynq Defibrillation Lead Abbott (NYSE: ABT) received both U.S. FDA approval and

Microchip Launches High-Speed Tactile Sensor Chip for Robotics and Physical AI Microchip Technology (NASDAQ: MCHP) introduced the ATFCD52, a high-speed

Carrier Launches SimplyFRESH Controlled Atmosphere System for Short-Haul Reefer Shipping Carrier Global (NYSE: CARR) introduced SimplyFRESH, a new controlled-atmosphere system

Johnson & Johnson Reports Second Positive Phase 3 Study for CAPLYTA in Bipolar Mania Johnson & Johnson (NYSE: JNJ) reported

Rockwell Automation Launches PanelView Pro to Modernize Industrial HMI Systems Rockwell Automation (NYSE: ROK) introduced PanelView Pro, a new high-performance

S&P 500Follow

NYSE:AFollow

NYSE:MCDFollow

Dividend Growth Stocks: McDonald's Corporation (MCD) Dividend Stock Analysis

'We know that consumers' behavior changes': McDonald's prepares for wider GLP-1 adoption as weight-loss pills hit market

Dividend Growth Stocks: McDonald's Corporation (MCD) Dividend Stock Analysis

How to analyse franchise stocks in 6 simple steps

AustraliaFollow

NASDAQ:AMGNFollow

NASDAQ:MSFTFollow

Tech stocks today: Nvidia stock rises as guidance signals AI boom alive and well

NYSE:IBMFollow

NYSE:QBTSFollow

USFollow

NASDAQ:FANGFollow

S&P 500

NYSE:A

NYSE:MCD

Australia

NASDAQ:AMGN

NASDAQ:MSFT

NYSE:IBM

NYSE:QBTS

US

NASDAQ:FANG